文献速递心力衰竭与心肌病

司美格鲁肽对射血分数保留的心力衰竭合并肥胖患者症状、功能和生活质量的影响:STEP-HFpEF 试验预设分析

Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial.
PubMed 文献 · Circulation · 2023-11-12

STEP-HFpEF 试验预设分析纳入 529 例症状性 HFpEF 且 BMI≥30 kg/m² 的患者,随机接受每周一次司美格鲁肽 2.4 mg 或安慰剂治疗 52 周。结果显示,无论基线 KCCQ-CSS 三分位如何,司美格鲁肽均改善 KCCQ-CSS、体重、6 分钟步行距离、炎症标志物和 NT-proBNP,并改善所有关键 KCCQ 域。

要点

  • 司美格鲁肽改善 HFpEF 合并肥胖患者的症状、功能和生活质量,不受基线健康状况影响。
  • 司美格鲁肽改善所有关键 KCCQ 域,且更多患者达到至少 5、10、15、20 分的改善。
  • 司美格鲁肽还改善 6 分钟步行距离、炎症标志物和 NT-proBNP。

核心结论

  • 在 HFpEF 合并肥胖患者中,司美格鲁肽对心力衰竭相关症状、体力限制、运动功能、炎症、体重和 NT-proBNP 产生大幅改善,且不依赖于基线健康状况。
  • 司美格鲁肽的获益扩展到所有关键 KCCQ 域。

研究设计与样本

  • STEP-HFpEF 试验为随机、安慰剂对照试验,纳入 529 例有症状、射血分数≥45% 且 BMI≥30 kg/m² 的心力衰竭患者。
  • 患者随机接受每周一次司美格鲁肽 2.4 mg 或安慰剂治疗 52 周。
  • 双主要终点为 KCCQ-临床总结评分(CSS)和体重的变化。
  • 确认性次要终点包括 6 分钟步行距离变化、分层复合终点(死亡、心衰事件、KCCQ-CSS 和 6 分钟步行距离变化)和 C 反应蛋白变化。
  • 患者按基线 KCCQ-CSS 三分位分层,评估司美格鲁肽对主要、确认性次要和探索性终点(NT-proBNP)的影响,并评估对额外 KCCQ 域的影响。

主要发现

  • 基线 KCCQ-CSS 三分位中位数分别为 37、59 和 77 分。
  • 司美格鲁肽在 KCCQ 三分位 1 至 3 中均持续改善主要终点:KCCQ-CSS 的估计治疗差异(95%CI)分别为 10.7(5.4 至 16.1)、8.1(2.7 至 13.4)和 4.6(-0.6 至 9.9)分;体重的估计治疗差异分别为 -11(-13.2 至 -8.8)、-9.4(-11.5 至 -7.2)和 -11.8(-14.0 至 -9.6);交互作用 P 值分别为 0.28 和 0.29。
  • 确认性次要和探索性终点也观察到类似结果(所有交互作用 P>0.1)。
  • 司美格鲁肽治疗患者在 all key KCCQ 域均改善(估计治疗差异 6.7-9.6 分;所有 P≤0.001)。
  • 司美格鲁肽治疗组比安慰剂组更大比例的患者在所有 KCCQ 域达到至少 5、10、15、20 分改善(比值比 1.6-2.9;所有 P<0.05)。

临床怎么用

  • 对于 HFpEF 合并肥胖患者,司美格鲁肽 2.4 mg 每周一次可考虑用于改善心力衰竭相关症状、体力限制和生活质量。
  • 司美格鲁肽的获益不受基线 KCCQ-CSS 评分影响,可考虑用于不同基线健康状况的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with heart failure (HF) with preserved ejection fraction (HFpEF) and obesity experience a high burden of symptoms and functional impairment, and a poor quality of life. In the STEP-HFpEF trial (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity), once-weekly semaglutide 2.4 mg improved symptoms, physical limitations, and exercise function, and reduced inflammation and body weight. This prespecified analysis investigated the effects of semaglutide on the primary and confirmatory secondary end points across the range of the Kansas City Cardiomyopathy Questionnaire (KCCQ) scores at baseline and on all key summary and individual KCCQ domains. METHODS: STEP-HFpEF randomly assigned 529 participants with symptomatic HF, an ejection fraction of ≥45%, and a body mass index of ≥30 kg/m2 to once-weekly semaglutide 2.4 mg or placebo for 52 weeks. Dual primary end points change in KCCQ-Clinical Summary Score (CSS) and body weight. Confirmatory secondary end points included change in 6-minute walk distance, a hierarchical composite end point (death, HF events, and change in KCCQ-CSS and 6-minute walk distance) and change in C-reactive protein. Patients were stratified by KCCQ-CSS tertiles at baseline. Semaglutide effects on the primary, confirmatory secondary, and select exploratory end points (N-terminal pro-brain natriuretic peptide) were examined across these subgroups. Semaglutide effects on additional KCCQ domains (Total Symptom Score [including symptom burden and frequency], Physical Limitations Score, Social Limitations Score, Quality of Life Score, and Overall Summary Score) were also evaluated. RESULTS: Baseline median KCCQ-CSS across tertiles was 37, 59, and 77 points, respectively. Semaglutide consistently improved primary end points across KCCQ tertiles 1 to 3 (estimated treatment differences [95% CI]: for KCCQ-CSS, 10.7 [5.4 to 16.1], 8.1 [2.7 to 13.4], and 4.6 [-0.6 to 9.9] points; for body weight, -11 [-13.2 to -8.8], -9.4 [-11.5 to -7.2], and -11.8 [-14.0 to -9.6], respectively; Pinteraction=0.28 and 0.29, respectively); the same was observed for confirmatory secondary and exploratory end points (Pinteraction>0.1 for all). Semaglutide-treated patients experienced improvements in all key KCCQ domains (estimated treatment differences, 6.7-9.6 points across domains; P≤0.001 for all). Greater proportion of semaglutide-treated versus placebo-treated patients experienced at least 5-, 10-, 15-, and 20-point improvements in all KCCQ domains (odds ratios, 1.6-2.9 across domains; P<0.05 for all). CONCLUSIONS: In patients with HFpEF and obesity, semaglutide produced large improvements in HF-related symptoms, physical limitations, exercise function, inflammation, body weight, and N-terminal pro-brain natriuretic peptide, regardless of baseline health status. The benefits of semaglutide extended to all key KCCQ domains. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04788511.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Kosiborod, Verma, Borlaug, et al. Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial. Circulation. 2023. PMID: 37952180. doi:10.1161/CIRCULATIONAHA.123.067505

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。